Palo Alto Investors »

Bluebird Bio shares owned by Palo Alto Investors

Quarter-by-quarter ownership of Bluebird Bio (BLUE) shares owned by Palo Alto Investors from 13F filings

Historical chart of Palo Alto Investors investment in Bluebird Bio

Tip: Access up to 7 years of quarterly data

All positions including Bluebird Bio held by Palo Alto Investors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Bluebird Bio by Palo Alto Investors

Quarter filed Position value Share count Share price at filing
2023-12-31 $4.6M 3.3M 1.38

More positions owned by Palo Alto Investors

Insmed Com Par $.01 (INSM)
Amicus Therapeutics (FOLD)
BioMarin Pharmaceutical (BMRN)
Biogen Idec (BIIB)
United Therapeutics Corporation (UTHR)
ACADIA Pharmaceuticals (ACAD)
Prothena Corp SHS (PRTA)
Revance Therapeutics (RVNC)
Staar Surgical Com Par $0.01 (STAA)
Alnylam Pharmaceuticals (ALNY)
eHealth (EHTH)
Sage Therapeutics (SAGE)
Sarepta Therapeutics (SRPT)
Iovance Biotherapeutics (IOVA)
Alkermes SHS (ALKS)

View all positions for Palo Alto Investors

Top funds holding Bluebird Bio

Vanguard Group
Alyeska Investment Group
Norges Bank Investment Management
Millennium Management
Palo Alto Investors
Dimensional Fund Advisors
Two Sigma Investments
Bleichroeder
Citadel Advisors
Hudson Bay Capital Management
Partner Fund Management
Jpmorgan Chase & Co
Frazier Life Sciences Management
Tang Capital Management
Bank of America Corporation

View all funds holding Bluebird Bio